Centiva Capital’s Bellevue Life Sciences Acquisition Corp. Rights BLACR Stock Holding History

Centiva Capital’s Portfolio BLACR Stock Details BLACR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-100,000	Closed	-$12K	–	2274
2024 Q4	$12K	Hold	100,000	–	–	﹤0.01%	1574
2024 Q3	$10.4K	Hold	100,000	–	–	﹤0.01%	2052
2024 Q2	$11.1K	Hold	100,000	–	–	﹤0.01%	1982
2024 Q1	$15K	Hold	100,000	–	–	﹤0.01%	1679
2023 Q4	$15K	Hold	100,000	–	–	﹤0.01%	1680
2023 Q3	$28K	Hold	100,000	–	–	﹤0.01%	1631
2023 Q2	$23K	Buy	+100,000	New	+$17.4K	﹤0.01%	1538

Centiva Capital's BLACR Position: Q1 2025 in Review

Centiva Capital sold out of Bellevue Life Sciences Acquisition Corp. Rights (BLACR) in Q1 2025, closing a stake of 100,000 shares — an estimated $12K sold.

Centiva Capital first reported a position in BLACR in Q2 2023 and held it in 7 quarters. The position peaked at $28K in Q3 2023. 0 funds tracked by Wall St. Rank hold BLACR as of Q1 2025.

Centiva Capital reported no remaining Bellevue Life Sciences Acquisition Corp. Rights position as of Q1 2025 after selling out during the quarter.
Centiva Capital sold 100,000 Bellevue Life Sciences Acquisition Corp. Rights shares in Q1 2025, an estimated $12K.
Centiva Capital first reported a position in Bellevue Life Sciences Acquisition Corp. Rights in Q2 2023 and held it in 7 quarters.
Centiva Capital's Bellevue Life Sciences Acquisition Corp. Rights position peaked at $28K in Q3 2023.
0 funds tracked by Wall St. Rank held Bellevue Life Sciences Acquisition Corp. Rights as of Q1 2025.

Based on Centiva Capital's 13F filing for Q1 2025, filed 15 May 2025.